NCT04459702

A Study of Combination Therapies to Treat COVID-19 Infection

A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: ProgenaBiome · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study seeks to determine whether dual or quadruple therapy is more effective in treating COVID-19.

Detailed description

In this study, patients will be administered either dual or quadruple therapy and have PCR tests run daily to determine efficacy as indicated by time to non-infectivity

Conditions

• COVID
• COVID-19
• Corona Virus Infection
• Coronavirus Infection
• Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
• Coronavirus-19
• SARS-CoV 2
• SARS Pneumonia

Interventions

Type	Name	Description
DRUG	hydroxychloroquine	Treatment with the drug hydroxychloroquine
DRUG	Azithromycin	Treatment with the drug azithromycin
DRUG	Ritonavir	Treatment with the drug ritonavir
DRUG	Lopinavir	Treatment with the drug lopinavir

Timeline

• Start date: 2020-07-01
• Primary completion: 2021-07-01
• Completion: 2021-12-01
• First posted: 2020-07-07
• Last updated: 2021-04-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study